June 25 (Reuters) - Hoth Therapeutics Inc HOTH.O:
SILO PHARMA: FORMATION OF STRATEGIC JOINT VENTURE WITH HOTH THERAPEUTICS
SILO PHARMA: JOINT VENTURE TO DEVELOP FIRST-IN-CLASS GDNF-BASED THERAPY LICENSED FROM U.S. DEPARTMENT OF VETERANS AFFAIRS
Source text: ID:nPn4b6dFMa
Further company coverage: HOTH.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.